A biologic’s efficacy in a pill: Dice posts first human data for oral psoriasis med

Dice Therapeutics reported the first human data for its oral psoriasis drug designed to hit the same pro-inflammatory protein blocked by blockbuster antibody drugs from Novartis and Eli Lilly. The potential for Dice’s pill to offer a competitive oral alternative pushed the biotech’s stock skyward by nearly 80%.